156603-10-0

Basic information

• Product Name: 1-BROMO-3-(1,3-DIOXOLAN-2-YL)-4-METHOXYBENZENE
• Synonyms: 2-(5-Bromo-2-methoxyphenyl)-1,3-dioxolane;RARECHEM AL BP 0053;1-BROMO-3-(1,3-DIOXOLAN-2-YL)-4-METHOXYBENZENE
• CAS NO: 156603-10-0
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.1
• Mol File: 156603-10-0.mol

Chemical Properties

• Boiling Point: 313.836°C at 760 mmHg
• Flash Point: 126.594°C
• Appearance: /
• Density: 1.479g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.551
• CAS DataBase Reference: 1-BROMO-3-(1,3-DIOXOLAN-2-YL)-4-METHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-3-(1,3-DIOXOLAN-2-YL)-4-METHOXYBENZENE(156603-10-0)
• EPA Substance Registry System: 1-BROMO-3-(1,3-DIOXOLAN-2-YL)-4-METHOXYBENZENE(156603-10-0)

Safety Data

• Hazardous Substances Data: 156603-10-0(Hazardous Substances Data)

Usage

Derivative of benzene

Yes

Explanation

The compound is derived from benzene, which is a hydrocarbon with a six-carbon ring structure and delocalized pi electrons.

Explanation

The presence of a bromine atom (Br) in the compound contributes to its reactivity and properties.

Explanation

A methoxy group (-OCH3) is a functional group consisting of an oxygen atom bonded to a methyl group. It is present in this compound, affecting its reactivity and properties.

Explanation

A dioxolane ring is a four-membered ring containing two oxygen atoms. It is part of the compound's structure, contributing to its unique properties.

Explanation

The compound is used as a reagent in organic synthesis to create other chemical compounds, due to its reactive functional groups.

Explanation

Its unique structure and potential for producing biologically active compounds make it valuable in the development of new pharmaceuticals.

Explanation

Bromine compounds can be hazardous, and appropriate safety measures should be taken when handling this compound.

Explanation

To minimize the risk of exposure to hazardous bromine compounds, it is essential to work in a well-ventilated area and follow proper safety protocols.

Contains a bromine atom

Yes

Contains a methoxy group

Yes

Contains a dioxolane ring

Yes

Used in organic synthesis

Yes

Used in pharmaceutical research and development

Yes

Hazardous nature

Yes

Handling precautions

Well-ventilated area, appropriate safety measures

InChI:InChI=1/C10H11BrO3/c1-12-9-3-2-7(11)6-8(9)10-13-4-5-14-10/h2-3,6,10H,4-5H2,1H3

Upstream product

• 107-21-1 ethylene glycol 
• 25016-01-7 5-bromo-2-methoxybenzaldehyde 

Downstream Products

• 464190-53-2 4-(3-[1,3]-dioxolan-2-yl-4-methoxy-phenyl)-1,2-dimethyl-1H-imidazole 
• 892483-05-5 2-(1,3-dioxolan-2-yl)-4-(4-pyridinyl)anisole 
• 156603-11-1 2-(5-methylthio-2-methoxyphenyl)-1,3-dioxolane 
• 197654-64-1 1-(3-formyl-4-methoxyphenyl)cyclopropanecarbonitrile 
• 1291094-36-4 (2S,3R,4R,5S,6R)-2-[4-methoxy-3-(spiro[chromane-2,1'-cyclobutane]-6-ylmethyl)phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol 
• 1291094-34-2 6-(2-methoxy-5-((2S,3S,4R,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)tetrahydro-2H-pyran-2-yl)benzyl)spiro[chroman-2,1'-cyclobutane] 
• 212128-85-3 (o-anisaldehyde ethylene acetal)ferrocene 
• 212128-88-6 1,1'-bis(o-anisaldehyde ethylene acetal)ferrocene 
• 892483-03-3 2-(1,3-dioxolan-2-yl)-4-N-morpholinylanisole 

Relevant articles and documents

ALPHAvBETA1 INTEGRIN ANTAGONISTS

The present disclosure provides pharmaceutical agents, including those of the formula: (I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents are also provided. The compounds may be used for the inhibition or antagonism of integrins ανβ1 and/or α5β1. In some embodiments, the compounds provided herein exhibit reduced inhibitory or antagonistic activity of integrins ανβ3, ανβ5, ανβ6, ανβ8, and/or αIIbβ3.

Ruthenium-catalyzed enantioselective C-H functionalization: A practical access to optically active indoline derivatives

Ru(II)-catalyzed enantioselective C-H activation/hydroarylation has been developed for the first time, allowing for highly enantioselective synthesis of indoline derivatives via catalytic C-H activation. Commercially available Ru(II) arene complexes and chiral α-methylamines were employed as highly enantioselective catalysts. Based on a sterically rigidified chiral transient directing group, multisubstituted indolines were produced in up to 92% yield with 96% ee. Further transformation of the resulting 4-formylindoline enables access to an optically active tricyclic compound that is of potential biological and pharmaceutical interest.

Substituted Pyrrolidines and Methods of Use

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

GLYCOSIDE DERIVATIVES AND USES THEREOF

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment

Glycoside Derivatives and Uses Thereof

This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

Redox-active Schiff base ligands

The syntheses and characterisation of two redox-active Schiff base ligands containing ferrocene are described, and their complex formation with Cu+ and Ag+ examined by UV/vis and 1H-, 13C-NMR spectroscopy, cyclic voltammetry and X-ray crystallography. Crystals of the complex formed between bis-(3-ethylenedi-imino-4-methoxyphenyl)ferrocene and AgBF4 belong to the highly unusual cubic system and spontaneous resolution of the helical, tetrahedral complex is observed.

Substituted quinuclidines as substance P antagonists

Certain novel substituted quinuclidine compounds having the ability to antagonize substance P and having the following formula: STR1 wherein Ar1 and Ar2 are each, independently, thienyl, phenyl, fluorophenyl, chlorophenyl or bromophenyl; X is --CONR3 R4, --CO2 R3, --CH2 OR3, --CH2 NR3 R4 or --CONR3 OR4 ; R1, R3 and R4 are each, independently, hydrogen or alkyl having 1 to 4 carbon atoms; R2 is alkyl having 1 to 4 carbon atoms; Y is alkylsulfonyl having 1 to 4 carbon atoms, N-alkyl-N-alkanoylamino (which may be substituted by halogen in the alkanoyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkanoyl moieties, N-alkyl-N-alkylsulfonylamino (which may be substituted by halogen in the alkylsulfonyl moiety) having 1 to 4 carbon atoms in the alkyl and the alkyl sulfonyl moieties, alkenyl having 2 to 4 carbon atoms, alkynyl having 2 to 4 carbon atoms, halosubstituted alkyl having 1 to 4 carbon atoms, alkylamino having 1 to 4 carbon atoms, alkanoylamino (which may be substituted by halogen) having 1 to 4 carbon atoms or alkylsulfonylamino (which may be substituted by halogen) having 1 to 4 carbon atoms. These compounds are useful in the treatment gastrointestinal or central nervous system disorders and the alleviation of inflammatory diseases, asthma, pain and migraine in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.